OncoMatch/Clinical Trials/NCT06799195
Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation
Is NCT06799195 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Attenuated-dose Cyclophosphamide and High-dose Cyclophosphamide for hematological malignancies.
Treatment: Attenuated-dose Cyclophosphamide · High-dose Cyclophosphamide · Sirolimus · Mycophenolate Mofetil (MMF) — This study will compare post-transplant health-related quality of life following the use of standard versus attenuated dose of post-transplant cyclophosphamide in addition to two-drug graft-versus-host disease (GVHD) prophylaxis among recipients of allogeneic hematopoietic stem cell transplant.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Demographics
Prior therapy
Cannot have received: allogeneic stem cell transplant
Lab requirements
Kidney function
Creatinine clearance less than 40 mL/min/1.73 m² [excluded]
Liver function
Known diagnosis of liver cirrhosis or other advanced liver disease that may impact cyclophosphamide metabolism [excluded]
Cardiac function
Systolic cardiac dysfunction with an ejection fraction of less than 45% [excluded]
Known diagnosis of liver cirrhosis or other advanced liver disease that may impact cyclophosphamide metabolism. Creatinine clearance less than 40 mL/min/1.73 m². Systolic cardiac dysfunction with an ejection fraction of less than 45%.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Nebraska Medical Center · Omaha, Nebraska
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06799195 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogeneic stem cell transplant disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify